Illumina (NASDAQ:ILMN) SVP Christensen Jakob Wedel Sells 700 Shares
by Doug Wharley · The Cerbat GemIllumina, Inc. (NASDAQ:ILMN – Get Free Report) SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Illumina Trading Down 2.7%
ILMN opened at $138.71 on Friday. The company’s 50 day moving average is $126.86 and its 200-day moving average is $127.86. Illumina, Inc. has a 1-year low of $75.24 and a 1-year high of $155.53. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a market cap of $20.99 billion, a P/E ratio of 25.22, a PEG ratio of 2.36 and a beta of 1.42.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Barclays boosted their price objective on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Evercore restated an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Piper Sandler lowered their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Finally, Robert W. Baird set a $137.00 target price on shares of Illumina in a research report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $131.06.
Check Out Our Latest Stock Analysis on ILMN
Hedge Funds Weigh In On Illumina
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Earned Wealth Advisors LLC raised its holdings in Illumina by 3.2% during the 1st quarter. Earned Wealth Advisors LLC now owns 5,513 shares of the life sciences company’s stock worth $680,000 after purchasing an additional 173 shares during the last quarter. Meeder Advisory Services Inc. boosted its stake in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the last quarter. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the period. Dimensional Fund Advisors LP raised its stake in Illumina by 3.3% during the first quarter. Dimensional Fund Advisors LP now owns 582,797 shares of the life sciences company’s stock worth $71,822,000 after buying an additional 18,602 shares during the last quarter. Finally, KBC Group NV raised its stake in Illumina by 2.1% during the first quarter. KBC Group NV now owns 45,953 shares of the life sciences company’s stock worth $5,664,000 after buying an additional 946 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.